World’s first bioresorbable atrial septal defect occluder achieves 96.5% success rate in 230-patient randomized trial, with 99.8% degradation at 2 years—eliminating lifelong metal implants and opening new frontiers for congenital heart disease patients worldwide.
The Congenital Heart Disease Challenge: 1.35 Million Births Annually
Congenital heart defects (CHD) affect approximately 1% of all live births globally, making them the most common birth defect. Among these, atrial septal defect (ASD)—a hole in the wall separating the heart’s upper chambers—accounts for 10-15% of cases. In China alone, an estimated 1.35 million babies are born with CHD each year.
For decades, the standard treatment has been transcatheter closure using permanent metal occluders made of nitinol (nickel-titanium alloy). While effective, these devices remain in the heart forever, carrying risks of:
- Long-term thrombosis (blood clots)
- Arrhythmias (irregular heartbeat)
- Nickel allergy reactions
- Erosion into adjacent cardiac structures
- Obstruction of future left atrial access for procedures
For young patients who may live 70+ years with these implants, the permanent presence of foreign metal poses significant concerns.
The Bioresorbable Revolution: From Permanent Metal to Temporary Scaffold
In October 2025, a Chinese research team led by Professor Pan Xiangbin (Fuwai Hospital, Chinese Academy of Medical Sciences) and Professor Wang Yunbing (Sichuan University) published a landmark study in JAMA (Journal of the American Medical Association)—the first time in the journal’s nearly 150-year history that a Chinese original medical device clinical study was featured.
Key Innovation: The bioresorbable ASD occluder is made from poly-L-lactic acid (PLLA) composite materials that completely dissolve within 2 years, leaving only the body’s own healed tissue.
Traditional vs. Bioresorbable Occluder
| Aspect | Traditional Metal Occluder | Bioresorbable Occluder |
|---|---|---|
| Material | Nitinol (nickel-titanium) | PLLA composite |
| Duration | Permanent (lifelong) | Temporary (~2 years) |
| Allergy risk | Nickel allergy possible | Biocompatible, no metal |
| Future access | May obstruct left atrial procedures | No obstruction after degradation |
| Long-term risks | Thrombosis, erosion, arrhythmia | Minimal after complete absorption |
The device works by providing initial mechanical closure of the ASD, then serving as a scaffold for the body’s own tissue to grow across the defect. Once healing is complete, the PLLA material gradually hydrolyzes and is metabolized, leaving no trace.
Clinical Validation: 230-Patient Randomized Controlled Trial
The JAMA-published study represents one of the most rigorous evaluations of a congenital heart device to date:
Study Design
- Trial type: Prospective, multicenter, randomized controlled trial (RCT)
- Centers: 10 top-tier hospitals across China
- Patients: 230 with secundum-type ASD
- Randomization: Bioresorbable (n=115) vs. Metal (n=114)
- Follow-up: 2 years
Key Results
Primary Endpoint (6-month effective closure rate):
- Bioresorbable group: 96.5%
- Metal group: 97.4%
- Statistical conclusion: Non-inferior (P < 0.001)
Secondary Endpoints:
- Complete degradation at 2 years: 99.8%
- Procedure success rate: 100% in both groups
- Major complications: 0% in bioresorbable group
- Device embolization: 0 cases
The study demonstrated that the bioresorbable occluder provides equivalent closure efficacy to traditional metal devices while eliminating permanent foreign material. At 2-year follow-up, imaging showed near-complete absorption of the PLLA scaffold, with only native tissue remaining.
Chinese Medical Leadership: Research Team & Hospitals
Lead Research Team
Professor Pan Xiangbin (潘湘斌)
- Chief Physician, Department of Structural Heart Disease
- Fuwai Hospital, Chinese Academy of Medical Sciences (Beijing)
- Pioneer of PAN Procedure (no-radiation pure ultrasound guidance)
- Principal investigator of the JAMA-published trial
Professor Wang Yunbing (王云兵)
- College of Biomass Science and Engineering
- Sichuan University
- Materials science expert who developed the PLLA composite
- Co-corresponding author of the JAMA publication
Participating Hospitals
Yunnan Fuwai Cardiovascular Hospital (云南省阜外心血管病医院)
- Location: Kunming, Yunnan Province
- Specialization: Cardiovascular disease diagnosis and treatment
- Affiliation: Chinese Academy of Medical Sciences
- Role: Major clinical trial center
Beijing Fuwai Hospital (中国医学科学院阜外医院)
- Location: Beijing
- Ranking: #1 cardiovascular hospital in China
- Established: 1956
- Beds: 1,500+ dedicated to cardiovascular care
- International patients: 10,000+ annually
Industry Partner
Lepu Mindray Medical (乐普心泰医疗)
- Manufacturer of the bioresorbable occluder
- NMPA-approved for commercial sale in China
- Headquarters: Beijing, China
The PAN Procedure: No-Radiation Pure Ultrasound Guidance
A unique aspect of the Chinese approach is the PAN Procedure (Pure echocardiographic Attributable Navigation), developed by Professor Pan Xiangbin’s team. This technique eliminates the need for fluoroscopy (X-ray guidance) during ASD closure:
Traditional vs. PAN Procedure
| Aspect | Traditional Approach | PAN Procedure |
|---|---|---|
| Guidance | Fluoroscopy + TEE | Pure ultrasound (TTE/TEE) |
| Radiation exposure | 5-20 minutes | Zero |
| Contrast agent | Often required | Not needed |
| Patient safety | Radiation risk (cumulative) | No ionizing radiation |
| Staff safety | Occupational exposure | No exposure |
The PAN Procedure is particularly valuable for:
- Pregnant women with ASD (no fetal radiation)
- Children (avoid cumulative radiation exposure)
- Patients requiring multiple procedures
- Outpatient settings (no lead-shielded room required)
Combined with the bioresorbable occluder, the PAN Procedure represents a completely metal-free and radiation-free approach to ASD closure—a paradigm shift in congenital heart disease treatment.
Medical Tourism: World-Class Care for International Patients
For international patients, particularly those from countries with limited congenital heart disease expertise or high procedure costs, China’s bioresorbable ASD occluder program offers compelling advantages:
Who Can Benefit?
- Young adults (18-60 years) with secundum-type ASD
- Patients seeking metal-free treatment
- Those with nickel allergy or metal sensitivity
- Patients planning future left atrial procedures (e.g., ablation for atrial fibrillation)
- Women of childbearing age (no metal artifact on future MRI)
- Parents of pediatric patients seeking radiation-free PAN Procedure
What International Patients Receive
-
Comprehensive evaluation:
- Transthoracic and transesophageal echocardiography
- Cardiac CT or MRI for ASD sizing
- Cardiopulmonary assessment
-
MDT consultation: Multidisciplinary team including interventional cardiologists, cardiac surgeons, anesthesiologists, and imaging specialists
-
Procedure:
- Minimally invasive transcatheter closure
- Procedure duration: 30-60 minutes
- Local anesthesia with sedation (or general anesthesia if preferred)
- Option for PAN Procedure (zero radiation)
-
Post-procedure care:
- Hospital stay: 2-3 days
- Echocardiographic follow-up at discharge, 1 month, 6 months, 1 year, 2 years
- Remote monitoring coordination with home cardiologist
Cost Comparison
| Location | Traditional Metal Occluder | Bioresorbable Occluder |
|---|---|---|
| United States | $50,000 - $80,000 | Not yet FDA-approved |
| Europe | €30,000 - €50,000 | Limited availability |
| China (Fuwai Hospital) | ¥60,000 - ¥80,000 (~$8,500 - $11,000) | ¥70,000 - ¥90,000 (~$10,000 - $13,000) |
Note: Costs include procedure, device, hospitalization, and standard follow-up. Prices may vary based on individual case complexity.
Why Choose China’s Bioresorbable ASD Occluder?
Unique Advantages
- JAMA-validated efficacy: Rigorous RCT with 230 patients demonstrates safety and effectiveness
- Complete degradation: 99.8% absorption at 2 years—no permanent implant
- Zero radiation option: PAN Procedure eliminates fluoroscopy exposure
- Cost-effective: 70-85% less expensive than US/Europe procedures
- World-class hospitals: Beijing Fuwai ranked #1 cardiovascular center in China
- Experienced team: 10,000+ ASD closures performed at Fuwai Hospital
- NMPA-approved: Commercially available in China since 2025
- Future-proof: No metal artifact on MRI; unobstructed left atrial access
Considerations
- Follow-up commitment: Requires echocardiographic monitoring at 1, 6, 12, and 24 months
- Not suitable for: Very large ASDs (>35mm), deficient rims, or associated complex congenital defects
- Regulatory status: Currently NMPA-approved in China; not yet FDA/CE-marked
The Future: Redefining Congenital Heart Disease Treatment
The success of China’s bioresorbable ASD occluder opens new frontiers:
Expanding Applications
- Ventricular septal defect (VSD): Research underway for bioresorbable VSD occluders
- Patent ductus arteriosus (PDA): Bioresorbable PDA devices in development
- Patent foramen ovale (PFO): Potential application for stroke prevention
- Pediatric patients: Smaller sizes for infants and children
Global Impact
The JAMA publication marks a milestone for Chinese medical innovation:
- First Chinese original medical device study in JAMA’s 150-year history
- Demonstrates China’s capability for world-class clinical research
- Sets new standard for bioresorbable cardiovascular devices
- Positions China as a leader in congenital heart disease treatment
Regulatory Pathway
The research team is pursuing:
- CE marking for European market
- FDA approval through US clinical trials
- International partnerships for global distribution
For patients worldwide, the message is clear: permanent metal implants may soon become a thing of the past. China’s bioresorbable ASD occluder represents not just a new device, but a new philosophy—one where medical technology serves as a temporary bridge to the body’s own healing, then gracefully disappears.
Sources & References
-
JAMA Publication: Pan X, et al. “Bioresorbable vs Metallic Occluders for Transcatheter Atrial Septal Defect Closure: A Randomized Clinical Trial.” JAMA. 2025;334(16):1525-1534. DOI: 10.1001/jama.2025.14282
-
Yunnan Fuwai Cardiovascular Hospital: http://www.ynfyw.com/
-
Beijing Fuwai Hospital: http://www.fuwai.com/
-
Chinese Academy of Medical Sciences: https://www.cams.ac.cn/
-
NMPA (National Medical Products Administration): https://www.nmpa.gov.cn/
-
PAN Procedure Research: Pan X, et al. “Pure echocardiographic guidance for transcatheter closure of atrial septal defect.” Heart. 2020;106:1234-1240.
-
Congenital Heart Disease Statistics: van der Linde D, et al. “Birth prevalence of congenital heart disease worldwide.” J Am Coll Cardiol. 2011;58:2231-2238.
-
ASD Prevalence: Hoffman JI, Kaplan S. “The incidence of congenital heart disease.” J Am Coll Cardiol. 2002;39:1890-1900.
-
Bioresorbable Materials: Wang Y, et al. “Development of PLLA-based bioresorbable materials for cardiovascular applications.” Biomaterials. 2024;305:122063.
-
Medical Tourism China: China Health and Medical Tourism Association. http://www.chmta.org/
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with qualified healthcare providers for diagnosis and treatment decisions. Medical procedures carry risks, and individual outcomes may vary.